Cargando…
Leptomeningeal Contrast Enhancement Is Associated with Disability Progression and Grey Matter Atrophy in Multiple Sclerosis
Leptomeningeal contrast enhancement (LMCE) on magnetic resonance imaging (MRI) is a newly recognized possible biomarker in multiple sclerosis (MS), associated with MS progression and cortical atrophy. In this study, we aimed to assess the prevalence of LMCE foci and their impact on neurodegeneration...
Autores principales: | Makshakov, Gleb, Magonov, Evgeniy, Totolyan, Natalia, Nazarov, Vladimir, Lapin, Sergey, Mazing, Alexandra, Verbitskaya, Elena, Trofimova, Tatiana, Krasnov, Vladimir, Shumilina, Maria, Skoromets, Alexander, Evdoshenko, Evgeniy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5643086/ https://www.ncbi.nlm.nih.gov/pubmed/29291134 http://dx.doi.org/10.1155/2017/8652463 |
Ejemplares similares
-
Diagnostic and Prognostic Value of the Cerebrospinal Fluid Concentration of Immunoglobulin Free Light Chains in Clinically Isolated Syndrome with Conversion to Multiple Sclerosis
por: Makshakov, Gleb, et al.
Publicado: (2015) -
COVID-19 Immunopathology and the Central Nervous System: Implication for Multiple Sclerosis and Other Autoimmune Diseases with Associated Demyelination
por: Boziki, Marina Kleopatra, et al.
Publicado: (2020) -
Dynamics of B-Cell Populations in CSF and Blood in Patients Treated with a Combination of Rituximab and Mitoxantrone
por: Evdoshenko, Evgeniy, et al.
Publicado: (2013) -
Real-world study of efficacy, risk management and reasons for discontinuation of natalizumab for treatment of multiple sclerosis in Russia
por: Evdoshenko, Evgeniy, et al.
Publicado: (2019) -
CD206-Targeted Liposomal Myelin Basic Protein Peptides in Patients with Multiple Sclerosis Resistant to First-Line Disease-Modifying Therapies: A First-in-Human, Proof-of-Concept Dose-Escalation Study
por: Belogurov, Alexey, et al.
Publicado: (2016)